Low Density Lipoprotein (LDL) News and Research

RSS

Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.

8 Jan 2013

Statin therapy affects muscles’ energy production

Up to 75 per cent of patients who take statins to treat elevated cholesterol levels may suffer from muscle pain. Scientists at the Center for Healthy Aging at the University of Copenhagen have now identified a possible mechanism underlying this unfortunate side effect.

4 Jan 2013

Juxtapid receives FDA approval for treatment of rare cholesterol disorder

On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.

27 Dec 2012

Few alcohol-related story ideas from The Methodist Hospital

The holidays are a time to consume -- food, gifts, and spirits. Here are a few alcohol-related story ideas from The Methodist Hospital. Because alcohol's effects on human physiology are complex, advice about is often contradictory.

20 Dec 2012

First meta-analytic review of association of perceived stress and incident CHD

Are you stressed? Results of a new meta-analysis of six studies involving nearly 120,000 people indicate that the answer to that question may help predict one's risk of incident coronary heart disease (CHD) or death from CHD.

17 Dec 2012

Dyslipidaemia: an interview with Prof. Peter Kokkinos

Dyslipidemia is defined as abnormal levels of blood lipids (fats) and cholesterol. The most common dyslipidaemias are high blood cholesterol (Total Cholesterol) and triglyceride levels, high levels of low-density lipoprotein (LDL) cholesterol (‘bad’ cholesterol) and low levels of high-density lipoprotein (HDL) cholesterol (‘good’ cholesterol).

17 Dec 2012

Genesee Health Plan joins Disparities and Cardiac Health Program initiative

MPRO, Michigan's Quality Improvement Organization, announced that Genesee Health Plan is joining its Disparities and Cardiac Health Program, a special project headed by the Centers for Medicare & Medicaid Services.

15 Dec 2012

Consuming whole eggs may improve blood lipids, new research suggests

It is estimated that 34% of Americans are affected by an increasingly prevalent condition known as metabolic syndrome which is a combination of at least three of the following risk factors: large waistline, high triglycerides, low HDL cholesterol, high blood pressure and elevated blood sugar.

15 Dec 2012

Maintaining weight loss may improve cardiometabolic profile in postmenopausal women

When you're postmenopausal and overweight, losing weight is a good thing, but gaining back just a few pounds may actually be detrimental to your cardiovascular health.

10 Dec 2012

Children with HIV more likely to develop atherosclerosis

Children with HIV have a 2.5 fold increased risk of atherosclerosis, according to research presented at EUROECHO and other Imaging Modalities 2012. Antiretroviral treatment, lipid lowering drugs and prevention with healthy lifestyles are needed to prevent early death from cardiovascular disease.

5 Dec 2012

Scientists identify 15 new genetic regions associated with coronary artery disease

Fifteen new genetic regions associated with coronary artery disease have been identified by a large, international consortium of scientists - including researchers at the Stanford University School of Medicine - taking a significant step forward in understanding the root causes of this deadly disease. The new research brings the total number of validated genetic links with heart disease discovered through genome-wide association studies to 46.

3 Dec 2012

Combining statin treatment with better fitness improves survival in people with dyslipidaemia

Taking statins or being even modestly physically fit markedly improves survival in people with dyslipidaemia (abnormal levels of harmful blood fats/cholesterol), according to new research published Online First in The Lancet. But combining statin treatment with better fitness may do more to ward off death than either intervention alone.

29 Nov 2012

Study identifies metabolic factors related to bread's beneficial effects on cardiovascular health

According to a study, daily bread consumption, especially wholemeal bread, can prevent cardiovascular disease. The study has been led by the professor Rafael Llorach, Ramon y Cajal researcher from the Department of Nutrition and Bromatology at the Faculty of Pharmacy and from the Food and Nutrition Torribera campus of the University of Barcelona.

29 Nov 2012

Computational apolipoprotein estimates ‘reliable’ for cardiovascular risk

Computational estimates of apolipoprotein B and apolipoprotein A1 can be used as reliable markers for atherosclerosis, report researchers.

22 Nov 2012

Computational apolipoprotein estimates ‘reliable’ for CV risk

Computational estimates of apolipoprotein B and apolipoprotein A1 can be used as reliable markers for atherosclerosis, report researchers.

21 Nov 2012

High risk CVD patients more likely to receive prescriptions for cholesterol-lowering drugs

In a new study, Northwestern Medicine researchers found that patients at high risk for cardiovascular disease (CVD) are more likely to receive a prescription for cholesterol-lowering medication, and to achieve lower long-term cholesterol levels, when doctors use electronic health records (EHRs) to deliver personalized risk assessments via mail.

16 Nov 2012

Monoclonal antibody boosts cholesterol reduction

Adding a monoclonal antibody that blocks the breakdown of lipid receptors to atorvastatin therapy further reduces low-density lipoprotein cholesterol levels in patients with primary hypercholesterolemia, show study findings.

9 Nov 2012

Atherotech VAP Lipid Panel demonstrates accuracy in personalized heart disease risk assessment

Researchers using the Atherotech VAP Lipid Panel demonstrated the comprehensive lipid profile's accuracy in risk stratification through subclass measurement in two abstracts presented today at the American Heart Association (AHA) Scientific Sessions 2012.

8 Nov 2012

Arisaph’s ARI-3037MO well tolerated in healthy male and female volunteers

Arisaph Pharmaceuticals, Inc. announced today during an oral presentation at the American Heart Association (AHA) meeting in Los Angeles, CA that its niacin analog, ARI-3037MO, was extremely well tolerated in a single-ascending dose (SAD) and a multiple-ascending dose (MAD) trial in healthy male and female volunteers.

7 Nov 2012

Treatment with AMG 145 reduces LDL cholesterol

Amgen today announced that results from the LAPLACE-TIMI 57 and MENDEL Phase 2 studies evaluating AMG 145 in hypercholesterolemic patients with or without statins, respectively, showed that treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol.

7 Nov 2012